81 related articles for article (PubMed ID: 20571236)
21. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
Miyata Y; Sakai H; Hayashi T; Kanetake H
Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
[TBL] [Abstract][Full Text] [Related]
22. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
23. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K
Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
[TBL] [Abstract][Full Text] [Related]
24. Serum interleukin-12 levels in patients with gastric cancer.
Murakami S; Okubo K; Tsuji Y; Sakata H; Hamada S; Hirayama R
Surg Today; 2004; 34(12):1014-9. PubMed ID: 15580384
[TBL] [Abstract][Full Text] [Related]
25. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
26. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D
Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996
[TBL] [Abstract][Full Text] [Related]
27. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
28. IL-4 and reactive oxygen species are elevated in Egyptian patients affected with schistosomal liver disease.
Elsammak MY; Al-Sharkaweey RM; Ragab MS; Amin GA; Kandil MH
Parasite Immunol; 2008; 30(11-12):603-9. PubMed ID: 19067841
[TBL] [Abstract][Full Text] [Related]
29. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort.
Spitz MR; Barnett MJ; Goodman GE; Thornquist MD; Wu X; Pollak M
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1413-8. PubMed ID: 12433720
[TBL] [Abstract][Full Text] [Related]
30. Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer.
Aoki S; Yamada Y; Nakamura K; Taki T; Tobiume M; Honda N
Oncol Rep; 2006 Aug; 16(2):279-84. PubMed ID: 16820903
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis.
Ren Y; Poon RT; Tsui HT; Chen WH; Li Z; Lau C; Yu WC; Fan ST
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5996-6001. PubMed ID: 14676125
[TBL] [Abstract][Full Text] [Related]
32. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy.
Izycki T; Chyczewska E; Naumnik W; Talalaj J; Panek B; Ossolinska M
Exp Oncol; 2004 Dec; 26(4):316-9. PubMed ID: 15627066
[TBL] [Abstract][Full Text] [Related]
33. [Expression of IGF-I and IGF-IR in bladder cancer].
Xie QX; Lin XC; Zhang MF; Han CX; Guo YH
Ai Zheng; 2004 Jun; 23(6):707-9. PubMed ID: 15191677
[TBL] [Abstract][Full Text] [Related]
34. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy.
Andreadis C; Touloupidis S; Galaktidou G; Kortsaris AH; Boutis A; Mouratidou D
J Urol; 2005 Nov; 174(5):1771-5; discussion 1775-6. PubMed ID: 16217281
[TBL] [Abstract][Full Text] [Related]
35. [Serum concentration of insulin, C-peptide and insulin-like growth factor I in patients with colon adenomas and colorectal cancer].
Kaczka A; Kumor A; Pietruczuk M; Małecka-Panas E
Pol Merkur Lekarski; 2007 May; 22(131):373-5. PubMed ID: 17679371
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of tissue-polypeptide specific antigen (TPS) in bladder cancer.
Menendez V; Galan JA; Fernandez-Suarez A; Lopez S; Alcover J; Calpena R; Filella X
Anticancer Res; 2002; 22(6B):3713-6. PubMed ID: 12552981
[TBL] [Abstract][Full Text] [Related]
37. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
el-Ahmady O; Halim AB; el-Din AG
Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
[TBL] [Abstract][Full Text] [Related]
38. Serum interleukin-18 and nitric oxide activity in bladder carcinoma.
Bukan N; Sözen S; Coskun U; Sancak B; Günel N; Bozkirli I; Senocak C
Eur Cytokine Netw; 2003; 14(3):163-7. PubMed ID: 14656691
[TBL] [Abstract][Full Text] [Related]
39. Urine interleukin-8 as a marker of vesicoureteral reflux in infants.
Galanakis E; Bitsori M; Dimitriou H; Giannakopoulou C; Karkavitsas NS; Kalmanti M
Pediatrics; 2006 May; 117(5):e863-7. PubMed ID: 16585276
[TBL] [Abstract][Full Text] [Related]
40. [Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ].
Trapeznikova MF; Shibaeva AN; Ianshin AA; Urenkov SB; Mironova OS; Kazantseva IA; Kushlinskiĭ NE
Urologiia; 2004; (1):17-21. PubMed ID: 15022438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
